Tag archives: Pharmaceuticals and life sciences

Two PM(NOC) Actions Dismissed After Common Trial on Validity of Treatment Regimen Patent

The Federal Court has dismissed two infringement actions brought against defendants under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (Regulations), following a common trial on the validity of Canadian Patent No. 2,562,277 (277 Patent). The Court found that all the asserted claims – to uses for treating multiple sclerosis (MS) – were … Continue reading

Top Headlines of 2018

Last year ushered in a number of changes to the Canadian pharmaceutical and life sciences sector. 2018 also served as a year to explore the impacts of major intellectual property decisions and regulatory changes from 2017 including the impact of the Supreme Court’s decision in NEXIUM striking down the Promise Doctrine and the implementation of … Continue reading

Pharma in brief – TMOB dismisses section 45 proceedings for the trade-mark REMODULIN

Case: Blake, Cassels & Graydon LLP v United Therapeutics Corporation, 2017 TMOB 9 Trade-Mark: REMODULIN Nature of case: Summary expungement proceedingpursuant to section 45 of Trade-marks Act Successful party: United Therapeutics Corporation Date of decision: January 26, 2017 Summary The Trademarks Opposition Board (TMOB) accepted United Therapeutics Corporation’s evidence of use of the trade-mark REMODULIN … Continue reading
LexBlog